“The first quarter of 2021 marked a significant transition for Surface, and I am honored to become CEO during this very exciting time,” said
Recent Corporate Highlights:
February 11, 2021, Surface announced that Rob Ross, chief medical officer, would succeed Jeff Goateras CEO, effective April 1, 2021.
March 8, 2021, Surface entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF388, an investigational antibody therapy targeting IL-27, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1 study of SRF388 and will be evaluated in patients with solid tumors, with a focus on patients with liver cancer and kidney cancer.
March 29, 2021, the U.S. Food and Drug Administrationgranted Orphan Drug Designation for SRF617 for the treatment of patients with pancreatic cancer.
- Surface presented updated preclinical data on lead candidates SRF617 and SRF388 at the
American Association for Cancer Research(AACR) 2021 Annual Meeting, held virtually April 10-15. The poster presentations can be found in the Posters & Publications section of our website.
April 27, 2021, Surface announced the appointment of Henry Rathas chief business officer and the promotions of Alison O’Neill, M.D. to chief medical officer, and Jessica Feesto chief financial officer.
Selected Anticipated Near-term Corporate Milestones:
- SRF388 clinical data presentation at the
American Society of Clinical Oncology(ASCO) 2021 Annual Meeting, to be held virtually June 4-8, 2021.
- Webcast to provide data from ongoing SRF388 and SRF617 Phase 1 clinical studies, to be held on
Friday, June 4, 2021at 8:00 a.m. ET.
- Investigational new drug (IND) filing for SRF813, partnered with GlaxoSmithKline, anticipated in 2021.
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
For the first quarter ended
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a license agreement with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Cautionary Note Regarding Forward-Looking Statements:
Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions, and the negative of those terms. These forward-looking statements are based on Surface Oncology’s management’s current beliefs and assumptions about future events and on information currently available to management.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Surface Oncology’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, risks and uncertainties related to Surface Oncology’s ability to successfully develop SRF388 and SRF617 and its other product candidates through current and future milestones or regulatory filings on the anticipated timeline, if at all, the therapeutic potential of Surface Oncology’s product candidates, the risk that results from preclinical studies or early clinical trials may not be representative of larger clinical trials, the risk that Surface Oncology’s product candidates, including SRF388 and SRF617, will not be successfully developed or commercialized, the risks related to Surface Oncology’s dependence on third-parties in connection with its manufacturing, clinical trials and preclinical studies, and the potential impact of COVID-19 on our clinical and preclinical development timelines and results of operations. Additional risks and uncertainties that could affect Surface Oncology’s future results are included in the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ending December 31, 2020, which is available on the Securities and Exchange Commission’s website at www.sec.gov and Surface Oncology’s website at www.surfaceoncology.com.
Additional information on potential risks will be made available in other filings that Surface Oncology makes from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements contained in this press release are based on assumptions that Surface Oncology believes to be reasonable as of this date. Except as required by law, Surface Oncology assumes no obligation to update these forward-looking statements, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.
Selected Financial Information:
(In thousands, except share and per share amounts)
|Three months ended
|Statement of Operations Items||2021||2020|
|Collaboration revenue - related party||$||—||$||38,592|
|License related revenue||1,626||—|
|Research and development||10,544||11,288|
|General and administrative||5,641||4,787|
|Total operating expenses||16,185||16,075|
|Income (loss) from operations||(14,559||)||22,517|
|Interest and other income (expense), net||(1,002||)||53|
|Net income (loss)||(15,561||)||22,570|
|Net income (loss) per share attributable to common stockholders— basic||$||(0.37||)||$||0.81|
|Weighted average common shares outstanding— basic||41,619,362||27,977,145|
|Net income (loss) per share attributable to common stockholders— diluted||$||(0.37||)||$||0.74|
|Weighted average common shares outstanding— diluted||41,619,362||30,917,452|
|Selected Balance Sheet Items:|
|Cash, cash equivalents and marketable securities||$||171,017||$||175,141|
|Accounts payable and accrued expenses||7,754||12,122|
|Total stockholders’ equity||159,047||155,747|
Source: Surface Oncology, Inc.